Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baireisi Pill
- Development stage
- Unknown
- Lead developer
- Humanwell Healthcare
- Administration
- Oral
01
Overview
Baireisi Pill (白热斯丸) is a traditional Chinese medicine (TCM) compound preparation developed by Wuhan Humanwell Hi-Tech Industry for the treatment of stable vitiligo. Currently in Phase 3 clinical development, it is administered as an oral pill. As a Chinese patent medicine (CPM), it is intended to address the depigmentation associated with vitiligo, although its specific molecular targets and herbal constituents are not detailed in the provided clinical pipeline information. It represents a therapeutic option within the sponsor's dermatological portfolio.
- Brand names
- 白热斯丸
- Other names
- Baireisi PillBairesi Pill
Beyond the preview
Go deeper on Baireisi Pill.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baireisi Pill.